The Deal
Saturday, November 21, 
8:35 pm

Chromatin morphing into plant energy company

  Share     E-Mail    Discussion    Print Story

switchgrass.jpgWith ethanol now getting a bad rap for its energy inefficiency and for using up crops that could otherwise be used for food, farmers are looking for alternatives to make energy from crops other than corn. A company called Chromatin Inc. might be able to help.

The Chicago-based company has developed mini-chromosome technology that allows it to introduce multiple genes into a plant cell, helping to reduce the time and cost required to develop crop-based products, including medicines, biomaterials, textiles and nutritionally-improved foods. But its technology also is being used in the bioenergy market, targeting crops like switchgrass, miscanthus (another grass), sorghum and sugarcane, where the addition of certain traits can improve crop and sugar yield, and thus improve the output of the plants used for energy.

Chromatin on Wednesday announced it has raised $12.4 million in a Series C round led by Quantitative Financial Strategies Inc., with participation from new investor Malaysian Life Sciences Capital Fund and its existing investors, Burrill & Co., Venture Investors, Unilever Technology Ventures, Foragen Technology Ventures and Illinois Ventures.

Chromatin said it will use the money to aggressively enter the bioenergy feedstock market. The company raised a total of $12 million previously. -- David Shabelman

See Dec. 3 press release from Chromatin 

 



Continue reading below

Also on Dealscape





Post a comment




The Deal Pipeline

Deal Video


Inside The Deal: Avaya Inc.'s Mohamad Ali on the company's next target.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


Industry Insight

Easing the stress of distressed M&A

Corporate buyers face numerous complexities when trying to identify the right moment to purchase a distressed asset.


Editor's Note

Editor's letter: Nov. 16, 2009

Beneath the veneer of Wall Streeters beats the same heart, stirred by the same determinants of behavior.



©Copyright 2008, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.